Treatment Information

Xtandi (Formerly MDV3100) Approved by the FDA for Treatment of Hormone- and Chemotherapy-Resistant Prostate Cancers.

On August 31st, 2012, the Food and Drug Administration (FDA) approved MDV3100 (now known as Xtandi) for treatment of prostate cancers in men who have previously failed hormone and chemo therapies. (See the full story in the August 31st issue of the Prostate Cancer Foundation, PCF, NewsPulse). In its Phase III clinical trials, Xtandi increased median more »

An Example of Potential New Prostate Cancer (PC) Treatments on the Horizon. Killing PC Cells With Radioactive Gold Nanoparticles Containing a Component of Tea as the Targeting Agent.

Nanotechnology is finding potential applications in many areas of our lives including cancer.  [A nanometer is defined as one billionth of a meter or one ten millionth of a centimeter (there are 2.54 centimeters per inch).] Synthetic nanometer-sized particles (such as atoms, molecules or fragments thereof usually less than 100 nanometers in size) are being used in many more »

Treating Low-Risk, Localized Prostate Cancer Using MRI-Guided Focal Laser Therapy.

The National Cancer Institute (NCI), the largest of the institutes comprising the National Insitutes of Health (NIH) in Bethesda and Frederick, Maryland is sponsoring a clinical trial for men who have slow-growing prostate cancer confined to a small portion of the prostate gland (low-volume disease). In this pilot study which is being conducted at the NIH more »

MDV3100 (enzalutamide) Now Available in Eleven (11) States.

The progress of developing new treatments for advanced prostate cancer continues. MDV3100 (now called enzalutamide) is being developed by Medivation Inc. and Astellas Pharma Inc. It is now available in eleven states as part of additional clinical trials in prostate cancer patients who have failed hormonal therapy and who have been previously treated with docetaxel (taxotere).  Enzalutamide more »

Positive Treatment Developments from Three Sources.

  At the Feb. 2nd-4th, 2012 meeting of the American Society of Clinical Oncology (ASCO), positive results were presented for two different prostate cancer treatments both currently under late stage Phase III clinical development. The positive results led to the studies being stopped earlier than anticipated.  These two drugs, radium-223 chloride (Alpharadin) and MDV3100 were more »

Robotic-Assisted Prostatectomy May Not Reduce Surgical Side Effects.

Currently, four out of five prostatectomies are performed laparoscopically using robotic technology. It was hoped that such surgical techniques would demonstrate clear benefits such as fewer side effects when compared to the traditional open radical prostatectomy. A recent article appearing in the January 10th, 2012 issue of the National Cancer Institute (NCI) Cancer Bulletin concluded more »

November News Items: 1) Watchful-Waiting; 2) New drug TAK-700; 3) Use of Cryotherapy After Failure of Radiation or Brachytherapy.

1) The November 16th, 2011 issue of the Newsletter from Zero-The Project to End Prostate Cancer, published an interesting article from the New York Times entitled “A  Watch-and-Wait Prostate Cancer Treatment.”  The article focused on the PSA screening and subsequent actions that a man over the age of 70 can take to keep his prostate more »

MDV3100 Extends Life in Men Whose Prostate Cancer Had Failed Hormonal- and Chemotherapies.

Positive Phase 3 clinical trial results for the drug MDV3100 in men whose prostate cancers had progressed after failing hormonal therapy and chemotherapy have recently been reported in a special edition of the Prostate Cancer Foundation Newsletter, November 7th, 2011 (see http://www.pcf.org/site).  Such positive results were observed that the trial was stopped early and the more »

FDA Grants Fast Track Designation to Radium-223 Chloride (Alpharadin) for the Treatment of Hormone Refractory Prostate Cancer That Has Spread to the Bone.

At the annual American Society of Clinical Oncology (ASCO) meeting in Chicago in June 2011, the Prostate Cancer Foundation September 30th newsletter reported on promising Phase III clinical trial results for radium-223 chloride (alpharadin), an agent specifically being developed for cancer patients with bone metastases. The drug works by emitting small doses of alpha particle radiation that more »

Prostate Cancer Stem Cells: A New Target for Treating Hormone-Refractory Cancer.

It has been known for over 60 years that in general, prostate cancer cells respond to androgen deprivation (hormonal) therapy. At some point however, the prostate cells no longer respond (they become hormone-refractory) and levels of prostate-specific antigen (PSA) begin to rise. Treating this hormone-refractory prostate cancer remains a major challenge. There is now evidence more »

Information from Johns Hopkins: a) Use of Immunotherapies (Provenge, Prostvac) Against Prostate Cancer; and, b) Gleason Scores.

Provenge (sipuleucel-T) was the first approved prostate cancer therapy which uses a person’s immune system to fight the disease.  Its approval was limited to men with advanced prostate cancer who have not responded to other treatments like hormonal (androgen deprivation) therapy and are experiencing few or no symptoms. Cost and supply remain significant issues hindering more »

GOOD NEWS!!! New Regimens and Therapeutic Agents in the Pipeline; a Visit with my Oncologist.

Every six months, I have an appointment with my oncologist at the Moffitt Cancer Center, on the campus of the University of South Florida, in Tampa. Moffitt is a designated National Cancer Institute (NCI, National Institutes of Health, my former employer) Comprehensive Cancer Center, a highly-sought-after distinction. My oncologist had been highly recommended to me more »

Countering Weight Gain as a Result of Hormonal Therapy.

Benefits and risks accompany virtually every method of treatment. Hormonal therapy for prostate cancer is no exception. Potential risks include osteoporosis and bone fractures, cardiac effects, diabetes, depression, hot flashes and metabolic changes resulting in weight gain. (These issues are discussed on this website under “My Story”, 2009 entries of July 5th-27th, September 29th, October more »

FDA Approves Abiraterone (Zytiga) for Advanced Prostate Cancer

(An initial blog was published on this website on Jan. 8th, 2011, describing results from late stage clinical trials of abiraterone acetate in hormone-refractory prostate cancer patients.) On April 28th, the Food and Drug Administration (FDA) approved abiraterone (Zytiga) for the treatment of men with metastatic castration (hormone)-resistant prostate cancer (meaning the disease progresses despite more »

Promising results for the late-stage prostate cancer drug, MDV3100.

MDV 3100 is a promising new treatment under clinical development by Medivation, Inc. and Astellas Pharma Inc. for advanced prostate cancer patients who have already received chemotherapy with taxotere (docetaxel) as well as those who have not been treated with taxotere.  MDV3100 slows growth and induces cell death in bicalutamide (casodex)-resistant cancers via three complementary more »